I finally can get to editing and adding upon this section for the Gene Database after I found the GIANT collaborative project that was published back in one of the October editions in Nature magazine in 2010. This is the most comprehensive collection of gene that have at “significance” in height.

First, lets get through some terminology…

GIANT (Genetic Investigation of ANthropometric Traits consortium): is an international collaboration that seeks to identify genetic loci that modulate human body size and shape, including height and measures of obesity. The GIANT consortium is a collaboration between investigators from many different groups, institutions, countries, and studies, and the results represent their combined efforts. The primary approach has been meta-analysis of genome-wide association data and other large-scale genetic data sets. Anthropometric traits that have been studied by GIANT include body mass index (BMI), height, and traits related to waist circumference (such as waist-hip ratio adjusted for BMI, or WHRadjBMI). Thus far, the GIANT consortium has identified common genetic variants at hundreds of loci that are associated with anthropometric traits. (from Broad Institute website HERE)

SNP (Single Nucleotide Polymorphism): is a DNA sequence variation occurring when a single nucleotide — A, T, C or G — in the genome (or other shared sequence) differs between members of a biological species or paired chromosomes in an individual. (ie, two sequenced DNA fragments from different individuals, AAGCCTA to AAGCTTA, contain a difference in a single nucleotide. In this case we say that there are two alleles: C and T). Almost all common SNPs have only two alleles (from wikipedia article on SNP here)

GWAs (Genomic-Wide Association studies): In genetic epidemiology, a genome-wide association study (GWA study, or GWAS), also known as whole genome association study (WGA study, or WGAS), is an examination of many common genetic variants in different individuals to see if any variant is associated with a trait. GWAS typically focus on associations between single-nucleotide polymorphisms (SNPs) and traits like major diseases. These studies normally compare the DNA of two groups of participants: people with the disease (cases) and similar people without (controls). Each person gives a sample of DNA, from which millions of genetic variants are read using SNP arrays. If one type of the variant (one allele) is more frequent in people with the disease, the SNP is said to be “associated” with the disease. The associated SNPs are then considered to mark a region of the human genome which influences the risk of disease. (from wikipedia article on GWAs here)

Nucleotide: molecules that, when joined, make up the individual structural units of the nucleic acids RNA and DNA.

Gene variation: variation in alleles of genes, occurs both within and among populations. Genetic variation is important because it provides the “raw material” for natural selection. Genetic variation is brought about by mutation, which is a change in the chemical structure of a gene. (from wiki)

Allele: one of two or more forms of a gene or a genetic locus (generally a group of genes). Sometimes, different alleles can result in different observable phenotypic traits, such as different pigmentation. However, many variations at the genetic level result in little or no observable variation. Most multicellular organisms have two sets of chromosomes, that is, they are diploid. These chromosomes are referred to as homologous chromosomes. Diploid organisms have one copy of each gene (and therefore one allele) on each chromosome. If both alleles are the same, they are homozygotes. If the alleles are different, they are heterozygotes. A population or species of organisms typically includes multiple alleles at each locus among various individuals. Allelic variation at a locus is measurable as the number of alleles (polymorphism) present, or the proportion of heterozygotes in the population.  In many cases, genotypic interactions between the two alleles at a locus can be described as dominant or recessive, according to which of the two homozygous genotypes the phenotype of the heterozygote most resembles. Where the heterozygote is indistinguishable from one of the homozygotes, the allele involved is said to be dominant to the other, which is said to be recessive to the former. The degree and pattern of dominance varies among loci. For a further discussion see Dominance (genetics). This type of interaction was first formally described by Gregor Mendel. However, many traits defy this simple categorization and the phenotypes are modeled by polygenic inheritance. The term “wild type” allele is sometimes used to describe an allele that is thought to contribute to the typical phenotypic character as seen in “wild” populations of organisms…Such a “wild type” allele was historically regarded as dominant, common, and “normal”, in contrast to “mutant” alleles regarded as recessive, rare, and frequently deleterious. It was commonly thought that most individuals were homozygous for the “wild type” allele at most gene loci, and that any alternative ‘mutant’ allele was found in homozygous form in a small minority of “affected” individuals, often as genetic diseases, and more frequently in heterozygous form in “carriers” for the mutant allele. It is now appreciated that most or all gene loci are highly polymorphic, with multiple alleles, whose frequencies vary from population to population, and that a great deal of genetic variation is hidden in the form of alleles that do not produce obvious phenotypic differences. (from wikipedia article on allele HERE)

Loci (singular is Locus): is the specific location of a gene or DNA sequence on a chromosome. A variant of the DNA sequence at a given locus is called an allele. The ordered list of loci known for a particular genome is called a genetic map. Gene mapping is the procession of determining the locus for a particular biological trait. Diploid and polyploid cells whose chromosomes have the same allele of a given gene at some locus are called homozygous with respect to that gene, while those that have different alleles of a given gene at a locus, are called heterozygous with respect to that gene. (from wikipedia article on gene loci HERE)

Gene: is a molecular unit of heredity of a living organism. It is a name given to some stretches of DNA and RNA that code for a polypeptide or for an RNA chain that has a function in the organism. A modern working definition of a gene is “a locatable region of genomic sequence, corresponding to a unit of inheritance, which is associated with regulatory regions, transcribed regions, and or other functional sequence regions “. Colloquial usage of the term gene (e.g. “good genes”, “hair color gene”) may actually refer to an allele: a gene is the basic instruction—a sequence of nucleic acids (DNA or, in the case of certain viruses RNA), while anallele is one variant of that gene. Referring to having a gene for a trait is no longer the scientifically accepted usage. In most cases, all people would have a gene for the trait in question, but certain people will have a specific allele of that gene, which results in the trait variant. Further, genes code for proteins, which might result in identifiable traits, but it is the gene, not the trait, which is inherited. (from the wikipedia article on gene HERE)

Minor Allele Frequency (MAF): refers to the frequency at which the less common allele occurs in a given population. MAF is widely employed in Genome Wide Association studies for complex traits. (from wikipedia article on MAF HERE)

Now let’s get through how gene locus nomenclature is done… 

 

(the segment/pic clip posted below is taken from the wikipedia article on genetics loci above HERE)

Also Understand the Results And Measurements (specifically the P-value)…

What is P-value? – In statistical hypothesis testing, the p-value is the probability of obtaining a test statistic at least as extreme as the one that was actually observed, assuming that the null hypothesis is true. One often “rejects the null hypothesis” when the p-value is less than the significance level α (Greek alpha), which is often 0.05 or 0.01. When the null hypothesis is rejected, the result is said to be statistically significant. (from wikipedia)

Note: For a far better and more detailed explanation of what exactly is the P-value please refer to the notes from a University of Alberta Stats class located HERE.

What does it mean to be “statistically significant”?

It has become scientific convention to say that p-values exceeding 0.05 (one in twenty) just aren’t strong enough to be the sole evidence that two treatments
being studied really differ in their effect. When the term statistically signicant is used to describe the results from a clinical trial, it means that the p-value is less than this conventional reference point. It is possible to have very strong evidence to show that even a very small effect is nonetheless a real one. Consequently, it is possible to have a small p-value even though the size of the effect is not worth bothering with from the 5clinical standpoint. Thus, statistical signicance and clinical importance must be completely separate assessments.

Even when one treatment is superior to another in clinically important ways, it is possible for the study not to end in statistical signicance. The study may have been too small to detect any but the largest of dierences. And of coursechance can work against a treatment as easily as work in its favor. Consequently, not achieving statistical signicance must not be interpreted as having shown that the treatments studied are equally effective. (from University of Chicago Document HERE)

List Of Genes

[Note: This list of genes that have a “significant” influence on height variation was all taken from the Supplementary Material from the GIANT project.]

Analysis 1 (from GIANT article)

 

If you can see close enough, you can see that there was 42 single nucleotide polymorphisms associated in the circular diagram above. As stated in the original article found HERE…

“This analysis revealed 17 different biological pathways and 14 molecular functions nominally enriched (P<0.05) for associated genes, many of which lie within the validated height loci. These gene-sets include previously reported (e.g. Hedgehog signaling) and novel (e.g. TGF-beta signaling, histones, and growth and development-related) pathways and molecular functions (Supplementary Table 12). Several SNPs near genes in these pathways narrowly missed genome-wide significance, suggesting that these pathways likely contain additional associated variants.”

also

“Of 32 genes with highly correlated (r²>0.8) nsSNPs, several are newly identified strong candidates for playing a role in human growth. Some are in pathways enriched in our study (such as ECM2, implicated in extracellular matrix), while others have similar functions to known growth-related genes, including FGFR4 (FGFR3 underlies several classic skeletal dysplasias²³) and STAT2 (STAT5B mutations cause growth defects in humans²⁴). Interestingly, Fgfr4-/- Fgfr3-/- mice show severe growth retardation not seen in either single mutant²⁵, suggesting that the FGFR4 variant might modify FGFR3-mediated skeletal dysplasias. Other genes at associated loci, such as NPPC and NPR3 (encoding the C-type natriuretic peptide and its receptor), influence skeletal growth in mice and will likely also influence human growth¹⁷. Many of the remaining 180 loci have no genes with obvious connections to growth biology, but at some our data provide modest supporting evidence for particular genes…”

COMPLETE LISTING – 180 gene loci at present 

[Note: All the tables, graphs, and charts are edited and taken from the Supplementary Document for the GIANT article located HERE.]

Supplementary Table 1. Association results for Stage 1 (discovery GWAS), Stage 2 (in-silico replication), Stage 1+2 combined, and Stage 1+2 sex-specific meta-analyses, for the 180 independent signals that reached genome-wide significance (P<5×10^-8) in the combined Stage 1+2 analysis. I² represents the % heterogeneity of effect size between Stage 1 studies. P_het is the heterogeneity P-value.

SNP a	Chr	Position (bp)	Nearest/OMIM height gene b	Effect / other allele c	Frequency (effect allele)	Beta	P-value d	Phet (MvsF)
rs425277	1	2059032	PRKCZ	T/C	0.28	0.024	1.70E-006	0.15
rs2284746	1	17179262	MFAP2	C/G	0.48	-0.035	5.60E-015	0.76
rs1738475	1	23409478	HTR1D	C/G	0.59	0.022	1.90E-006	0.25
rs4601530	1	24916698	CLIC4	T/C	0.26	-0.024	2.00E-006	0.47
rs7532866	1	26614131	LIN28	A/G	0.67	0.022	3.30E-006	0.23
rs2154319	1	41518357	SCMH1	T/C	0.75	-0.034	4.30E-010	0.13
rs17391694	1	78396214	GIPC2	T/C	0.12	0.04	5.90E-007	0.95
rs6699417	1	88896031	PKN2	T/C	0.61	0.022	1.70E-006	0.99
rs10874746	1	93096559	RPL5	T/C	0.37	-0.022	1.70E-006	0.78
rs9428104	1	118657110	SPAG17	A/G	0.24	-0.038	8.90E-013	0.55
rs11205277	1	148159496	SF3B4	A/G	0.58	-0.045	1.20E-018	0.36
rs17346452	1	170319910	DNM3	T/C	0.73	-0.038	3.30E-014	0.56
rs1325598	1	175058872	PAPPA2	A/G	0.43	-0.026	1.60E-008	0.52
rs1046934	1	182290152	TSEN15	A/C	0.64	-0.046	6.40E-022	0.94
rs10863936	1	210304421	DTL	A/G	0.53	-0.022	6.20E-007	0.06
rs6684205	1	216676325	TGFB2	A/G	0.71	-0.033	2.00E-011	0.41
rs11118346	1	217810342	LYPLAL1	T/C	0.47	-0.026	2.20E-009	0.05
rs10799445	1	225978506	JMJD4	A/C	0.77	0.031	1.20E-008	0.21
rs4665736	2	25041103	DNAJC27	T/C	0.54	0.034	1.40E-013	0.08
rs6714546	2	33214929	LTBP1	A/G	0.28	-0.025	2.20E-006	0.19
rs17511102	2	37814117	CDC42EP3	A/T	0.91	-0.06	1.30E-012	0.9
rs2341459	2	44621706	C2orf34	T/C	0.27	0.028	3.60E-008	0.14
rs12474201	2	46774789	SOCS5	A/G	0.35	0.023	1.00E-006	0.78
rs3791675	2	55964813	EFEMP1	T/C	0.23	-0.05	2.40E-020	0.71
rs11684404	2	88705737	EIF2AK3	T/C	0.67	-0.027	6.40E-009	0.46
rs7567288	2	134151294	NCKAP5	T/C	0.8	-0.031	6.70E-008	0.6
rs7567851	2	178392966	PDE11A	C/G	0.08	0.041	7.50E-007	0.7
rs1351164	2	217980143	TNS1	T/C	0.79	0.028	3.70E-007	0.83
rs12470505	2	219616613	CCDC108/IHH	T/G	0.9	0.048	1.30E-010	0.01
rs2629046	2	224755988	SERPINE2	T/C	0.55	0.025	2.20E-008	0.2
rs2580816	2	232506210	NPPC	T/C	0.19	-0.041	1.80E-012	0.23
rs12694997	2	241911659	SEPT2	A/G	0.24	-0.027	1.80E-007	0.61
rs2597513	3	13530836	HDAC11	T/C	0.9	-0.039	1.10E-007	0.83
rs13088462	3	51046753	DOCK3	T/C	0.94	-0.054	3.10E-007	0.56
rs2336725	3	53093779	RTF1	T/C	0.55	-0.026	3.50E-008	0.85
rs9835332	3	56642722	C3orf63	C/G	0.46	-0.022	8.70E-007	0.91
rs17806888	3	67499012	SUCLG2	T/C	0.88	0.04	1.10E-007	0.93
rs9863706	3	72520103	RYBP	T/C	0.22	-0.03	1.50E-008	0.6
rs6439167	3	130533446	C3orf47	T/C	0.21	-0.034	7.20E-010	0.09
rs9844666	3	137456906	PCCB	A/G	0.25	-0.028	3.10E-008	0.09
rs724016	3	142588260	ZBTB38	A/G	0.56	-0.067	4.50E-052	0.42
rs572169	3	173648421	GHSR	T/C	0.31	0.036	9.90E-014	0.4
rs720390	3	187031377	IGF2BP2	A/G	0.39	0.031	1.60E-010	0.14
rs2247341	4	1671115	SLBP/FGFR3	A/G	0.36	0.025	6.80E-008	0.67
rs6449353	4	17642586	LCORL	T/C	0.85	0.071	1.30E-027	0.88
rs17081935	4	57518233	POLR2B	T/C	0.2	0.031	4.80E-008	0.09
rs7697556	4	73734177	ADAMTS3	T/C	0.47	0.022	1.30E-006	0.56
rs788867	4	82369030	PRKG2/BMP3	T/G	0.68	-0.039	1.80E-015	0.95
rs10010325	4	106325802	TET2	A/C	0.49	0.021	2.30E-006	0.64
rs7689420	4	145787802	HHIP	T/C	0.16	-0.069	1.40E-029	0.61
rs955748	4	184452669	WWC2	A/G	0.24	-0.024	2.20E-006	0.29
rs1173727	5	32866278	NPR3	T/C	0.4	0.036	4.00E-015	0.27
rs11958779	5	55037656	SLC38A9	A/G	0.7	-0.028	8.00E-009	0.8
rs10037512	5	88390431	MEF2C	T/C	0.56	0.027	3.80E-009	0.3
rs13177718	5	108141243	FER	T/C	0.07	-0.041	4.10E-006	0.16
rs1582931	5	122685098	CEP120	A/G	0.47	-0.025	2.10E-008	0.31
rs274546	5	131727766	SLC22A5	A/G	0.4	-0.028	8.50E-010	0.13
rs526896	5	134384604	PITX1	T/G	0.73	0.032	1.90E-009	0.15
rs4282339	5	168188818	SLIT3	A/G	0.2	-0.035	3.40E-010	0.69
rs12153391	5	171136043	FBXW11	A/C	0.25	-0.033	8.70E-010	0.57
rs889014	5	172916720	BOD1	T/C	0.36	-0.029	4.50E-010	0.51
rs422421	5	176449932	FGFR4/NSD1	T/C	0.22	-0.033	1.40E-009	0.64
rs6879260	5	179663620	GFPT2	T/C	0.39	-0.028	5.60E-010	0.41
rs3812163	6	7670759	BMP6	A/T	0.54	-0.037	6.70E-016	0.36
rs1047014	6	19949472	ID4	T/C	0.75	-0.029	1.10E-007	0.9
rs806794	6	26308656	Histone cluster	A/G	0.7	0.053	5.50E-026	0.12
rs3129109	6	29192211	OR2J3	T/C	0.39	-0.026	3.30E-008	0.64
rs2256183	6	31488508	MICA	A/G	0.45	0.035	2.70E-014	0.43
rs6457620	6	32771977	HLA locus	C/G	0.51	-0.024	3.60E-008	0.81
rs2780226	6	34307070	HMGA1	T/C	0.92	-0.079	1.00E-018	0.96
rs6457821	6	35510783	PPARD/FANCE	A/C	0.02	-0.121	1.80E-011	0.29
rs9472414	6	45054484	SUPT3H/RUNX2	A/T	0.22	-0.031	2.40E-008	0.66
rs9360921	6	76322362	SENP6	T/G	0.89	-0.048	4.60E-011	0.62
rs310405	6	81857081	FAM46A	A/G	0.52	0.03	3.60E-011	0.25
rs7759938	6	105485647	LIN28B	T/C	0.68	-0.042	8.70E-018	0.26
rs1046943	6	109890634	ZBTB24	A/G	0.58	0.022	8.60E-007	0.46
rs961764	6	117628849	VGLL2	C/G	0.42	-0.023	2.40E-007	0.79
rs1490384	6	126892853	C6orf173	T/C	0.5	0.037	3.20E-016	0.55
rs6569648	6	130390812	L3MBTL3	T/C	0.76	-0.036	8.90E-012	0.14
rs7763064	6	142838982	GPR126	A/G	0.29	-0.045	6.40E-019	0.29
rs543650	6	152152636	ESR1	T/G	0.4	-0.032	1.40E-009	0.36
rs9456307	6	158849430	TULP4	A/T	0.06	-0.05	4.60E-007	0.38
rs798489	7	2768329	GNA12	T/C	0.3	-0.052	8.50E-025	0.53
rs4470914	7	19583047	TWISTNB	T/C	0.18	0.033	3.80E-008	0.93
rs12534093	7	23469499	IGF2BP3	A/T	0.22	-0.03	5.60E-008	0.84
rs1708299	7	28156471	JAZF1	A/G	0.3	0.042	1.50E-017	0.25
rs6959212	7	38094851	STARD3NL	T/C	0.32	-0.023	2.80E-006	0.66
rs42235	7	92086012	CDK6	T/C	0.31	0.055	7.30E-028	0.01
rs822552	7	148281567	PDIA4	C/G	0.74	-0.03	1.30E-007	0.24
rs2110001	7	150147955	TMEM176A	C/G	0.69	-0.033	9.80E-010	0.71
rs1013209	8	24172249	ADAM28	T/C	0.25	-0.029	4.50E-008	0.95
rs7460090	8	57356717	SDR16C5	T/C	0.87	0.055	9.60E-016	0.16
rs6473015	8	78341040	PEX2	A/C	0.72	-0.032	1.70E-010	0.84
rs6470764	8	130794847	GSDMC	T/C	0.2	-0.047	5.90E-017	0.95
rs12680655	8	135706519	ZFAT	C/G	0.6	0.03	4.80E-011	0.45
rs7864648	9	16358732	BNC2	T/G	0.32	0.025	4.90E-007	0.23
rs11144688	9	77732106	PCSK5	A/G	0.11	-0.055	1.50E-009	0.28
rs7853377	9	85742025	C9orf64	A/G	0.77	-0.026	3.10E-006	0.26
rs8181166	9	88306448	ZCCHC6	C/G	0.53	0.025	1.10E-007	0.07
rs2778031	9	90025546	SPIN1	T/C	0.24	0.027	3.60E-007	0.78
rs9969804	9	94468941	IPPK	A/C	0.44	0.028	5.60E-010	0.92
rs1257763	9	95933766	PTPDC1	A/G	0.04	0.069	2.50E-006	0.55
rs473902	9	97296056	PTCH1/FANCC	T/G	0.92	0.074	1.70E-014	0.62
rs7027110	9	108638867	ZNF462	A/G	0.23	0.034	1.30E-010	0.72
rs1468758	9	112846903	LPAR1	T/C	0.25	-0.026	1.50E-006	0.24
rs751543	9	118162163	PAPPA	T/C	0.72	0.029	4.50E-008	0.89
rs7466269	9	132453905	FUBP3	A/G	0.64	0.036	1.20E-014	0.92
rs7849585	9	138251691	QSOX2	T/G	0.33	0.032	3.40E-011	0.69
rs7909670	10	12958770	CCDC3	T/C	0.44	-0.022	1.30E-006	0.06
rs2145998	10	80791702	PPIF	A/T	0.49	-0.025	2.70E-008	0.68
rs11599750	10	101795432	CPN1	T/C	0.38	-0.023	7.60E-007	0.32
rs2237886	11	2767307	KCNQ1	T/C	0.11	0.043	3.10E-008	0.25
rs7926971	11	12654616	TEAD1	A/G	0.55	-0.024	7.30E-008	0.4
rs1330	11	17272605	NUCB2	T/C	0.35	0.024	4.40E-007	0.56
rs10838801	11	48054856	PTPRJ/SLC39A13	A/G	0.69	-0.031	1.80E-010	0.27
rs1814175	11	49515748	FOLH1	T/C	0.34	0.023	2.60E-006	0.13
rs5017948	11	51270794	OR4A5	A/T	0.18	0.027	4.70E-006	0.02
rs3782089	11	65093395	SSSCA1	T/C	0.06	-0.058	5.90E-009	0.13
rs7112925	11	66582736	RHOD	T/C	0.35	-0.023	8.50E-007	0.57
rs634552	11	74959700	SERPINH1	T/G	0.14	0.041	1.40E-009	0.69
rs494459	11	118079885	TREH	T/C	0.41	0.021	4.90E-006	0.5
rs654723	11	128091365	FLI1	A/C	0.62	0.024	6.70E-007	0.82
rs2856321	12	11747040	ETV6	A/G	0.64	-0.03	1.50E-010	0.83
rs10770705	12	20748734	SLCO1C1	A/C	0.33	0.031	4.60E-011	0.77
rs2638953	12	28425682	CCDC91	C/G	0.68	0.036	8.40E-014	0.04
rs2066807	12	55026949	STAT2	C/G	0.93	-0.052	9.60E-009	0.49
rs1351394	12	64638093	HMGA2	T/C	0.49	0.054	7.80E-034	0.14
rs10748128	12	68113925	FRS2	T/G	0.35	0.035	3.80E-011	0.23
rs11107116	12	92502635	SOCS2	T/G	0.22	0.052	1.70E-023	0.1
rs7971536	12	100897919	CCDC53/GNPTAB	A/T	0.46	-0.025	1.10E-007	0.75
rs11830103	12	122389499	SBNO1	A/G	0.78	-0.035	3.80E-010	0.27
rs7332115	13	32045548	PDS5B/BRCA2	T/G	0.62	-0.025	7.60E-008	0.37
rs3118905	13	50003335	DLEU7	A/G	0.29	-0.052	3.00E-025	0.15
rs7319045	13	90822575	GPC5	A/G	0.4	0.029	4.50E-010	0.6
rs1950500	14	23900690	NFATC4	T/C	0.29	0.032	3.90E-011	0.32
rs2093210	14	60027032	SIX6	T/C	0.58	-0.034	2.30E-012	0.23
rs1570106	14	67882868	RAD51L1	T/C	0.2	-0.026	4.90E-006	0.67
rs862034	14	74060499	LTBP2	A/G	0.36	-0.023	1.10E-006	0.24
rs7155279	14	91555634	TRIP11	T/G	0.36	-0.029	8.90E-010	0.38
rs16964211	15	49317787	CYP19A1	A/G	0.05	-0.051	2.50E-006	0.04
rs7178424	15	60167551	C2CD4A	T/C	0.47	-0.024	2.20E-007	0.88
rs10152591	15	67835211	TLE3	A/C	0.91	0.045	3.50E-008	0.28
rs12902421	15	69948457	MYO9A	T/C	0.97	-0.069	1.70E-006	0.25
rs5742915	15	72123686	PML	T/C	0.54	-0.031	3.00E-010	0.08
rs11259936	15	82371586	ADAMTSL3	A/C	0.48	-0.042	2.20E-021	0.03
rs16942341	15	87189909	ACAN	T/C	0.03	-0.134	1.30E-017	0.43
rs2871865	15	97012419	IGF1R	C/G	0.88	0.054	1.10E-012	0.54
rs4965598	15	98577137	ADAMTS17	T/C	0.68	-0.035	1.40E-013	0.21
rs11648796	16	732191	NARFL	A/G	0.74	-0.031	2.40E-007	0.71
rs26868	16	2189377	CASKIN1	A/T	0.46	0.03	3.50E-008	0.73
rs1659127	16	14295806	MKL2	A/G	0.34	0.024	2.90E-006	0.7
rs8052560	16	87304743	CTU2/GALNS	A/C	0.79	0.039	1.40E-008	0.47
rs4640244	17	21224816	KCNJ12	A/G	0.61	0.028	2.00E-007	0.78
rs3110496	17	24941897	ANKRD13B	A/G	0.33	-0.023	1.60E-006	0.04
rs3764419	17	26188149	ATAD5/RNF135	A/C	0.39	-0.037	8.90E-016	0.67
rs17780086	17	27367395	LRRC37B	A/G	0.15	0.035	4.40E-008	0.85
rs1043515	17	34175722	PIP4K2B	A/G	0.45	-0.022	1.30E-006	0.15
rs4986172	17	40571807	ACBD4	T/C	0.35	-0.028	7.10E-009	0.41
rs2072153	17	44745013	ZNF652	C/G	0.3	0.026	6.70E-008	0.03
rs4605213	17	46599746	NME2	C/G	0.34	0.023	9.30E-007	0.21
rs227724	17	52133816	NOG	A/T	0.65	-0.027	1.20E-008	0.2
rs2079795	17	56851431	TBX2	T/C	0.33	0.04	1.20E-016	0.12
rs2665838	17	59320197	CSH1/GH1	C/G	0.73	-0.037	2.00E-013	0.92
rs11867479	17	65601802	KCNJ16/KCNJ2	T/C	0.34	0.024	4.90E-007	0.68
rs4800452	18	18981609	CABLES1	T/C	0.79	0.048	2.40E-017	0.8
rs9967417	18	45213498	DYM	C/G	0.58	-0.038	2.60E-016	0.44
rs17782313	18	56002077	MC4R	T/C	0.76	-0.025	3.50E-006	0.55
rs12982744	19	2128193	DOT1L	C/G	0.6	-0.033	2.80E-012	0.6
rs7507204	19	3379834	NFIC	C/G	0.24	0.028	2.30E-007	0.05
rs891088	19	7135762	INSR	A/G	0.74	-0.025	1.70E-006	0.45
rs4072910	19	8550031	ADAMTS10	C/G	0.46	-0.029	2.50E-007	0.31
rs2279008	19	17144303	MYO9B	T/C	0.74	0.031	2.40E-007	0.48
rs17318596	19	46628935	ATP5SL	A/G	0.36	0.029	3.00E-009	0.01
rs1741344	20	4049800	SMOX	T/C	0.63	-0.026	3.50E-008	0.55
rs2145272	20	6574218	BMP2	A/G	0.65	-0.039	5.90E-016	0.85
rs7274811	20	31796842	ZNF341	T/G	0.23	-0.04	6.80E-014	0.52
rs143384	20	33489170	GDF5	A/G	0.58	-0.064	4.90E-039	0.47
rs237743	20	47336426	ZNFX1	A/G	0.21	0.034	7.20E-010	0.28
rs2834442	21	34612656	KCNE2	A/T	0.65	0.027	7.30E-009	0.9
rs4821083	22	31386341	SYN3	T/C	0.84	0.033	4.80E-008	0.41

• ^a SNPs most likely to be representing a previously published height locus are highlighted in green.
• ^b Gene regions are named after the gene nearest to the index SNP. A near-by (within 500kb from the index SNP) OMIM height gene (defined as a gene that when mutated results in a monogenic skeletal growth defect) is also included if it is not the nearest. All OMIM height genes are highlighted in blue.
• ^c Alleles are indexed to the forward strand of NCBI Build 36.
• ^d All p-values are based on the inverse-variance weighted meta-analysis model (fixed effects).